DAX+0,06 % EUR/USD+0,42 % Gold-0,12 % Öl (Brent)-1,03 %

Health & Care Konferenz Boston ab 16.03.2003 - Sequenom ist dabei - 500 Beiträge pro Seite


ISIN: US8173374054 | WKN: A0J23S
2,110
31.08.16
Lang & Schwarz
+0,48 %
+0,010 EUR

Beitrag schreiben

Begriffe und/oder Benutzer

 

SAN DIEGO, Mar 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- SEQUENOM, Inc. (SQNM, Trade) announced today that it will be among the leading health care and biotechnology companies presenting at the SG Cowen 23rd Annual Health Care Conference, being held March 16 - 20 in Boston. Toni Schuh, Ph.D., SEQUENOM`s President and Chief Executive Officer, will present an overview of the Company, including recent developments and future milestones.


(Photo: http://www.newscom.com/cgi-bin/prnh/20011120/SQNMLOGO )
SG Cowen Health Care Conference Presentation - Live over the Internet
Date: March 18, 2003 9:00 a.m. EST
Speaker: Toni Schuh, Ph.D., President & CEO
Access: Available live at www.sequenom.com - Investors section

If you are unable to participate during the live webcast, the call will be archived until April 1, on the Company`s website www.sequenom.com .

(Minimum Requirements to listen to broadcast: Windows Media Player software or Real Player software and at least a 28.8Kbps connection to the Internet.)

About SEQUENOM

SEQUENOM is a leading genetics company organized into two distinct business units: SEQUENOM Genetic Systems and SEQUENOM Pharmaceuticals. The two business units combine to capitalize on the Company`s high performance DNA analysis platform, SNP assay portfolio, disease gene discovery programs and extensive DNA sample repository. The genetic systems unit is dedicated to the sales and support of SEQUENOM`s MassARRAY products and the continual expansion of platform applications. The pharmaceutical unit applies the power of human genetics to systematically identify disease-related genes that affect significant portions of the overall population. SEQUENOM Pharmaceuticals focuses on disease gene discovery, target identification, functional validation and ultimately diagnostic and therapeutic product development.


SEQUENOM(R) and MassARRAY(TM) are trademarks of SEQUENOM, Inc.

SOURCE SEQUENOM, Inc.


Mark Henshaw, Investor Relations, +1-858-202-9034,
mhenshaw@sequenom.com, or Media, Pete De Spain, Media Relations,
+1-858-202-9033, pdespain@sequenom.com, both of SEQUENOM, Inc.
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20011120/SQNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840

http://www.sequenom.com

Copyright (C) 2003 PR Newswire. All rights reserved.


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.